Journal article
Effect of rosiglitazone, metformin, and glyburide on bone biomarkers in patients with type 2 diabetes
B Zinman, SM Haffner, WH Herman, RR Holman, JM Lachin, BG Kravitz, G Paul, NP Jones, RP Aftring, G Viberti, SE Kahn, S Kahn, S Haffner, W Herman, P Aftring, N Jones
Journal of Clinical Endocrinology and Metabolism | Published : 2010
DOI: 10.1210/jc.2009-0572
Abstract
Context: An increase in bone fractures has been observed in women taking thiazolidinediones. Objective: The objective of the study was to examine whether changes in circulating bone biomarkers provide insight into the underlying mechanisms responsible for the increase in bone fractures in female participants randomized to rosiglitazone in A Diabetes Outcome Progression Trial (ADOPT). Research Design and Methods: Paired stored baseline and 12-month serum samples were available from 1605 participants (689 women, 916 men) in ADOPT, a long-term clinical trial comparing the effects of rosiglitazone, glyburide, and metformin on glycemic control in patients with type 2 diabetes. Results: This subse..
View full abstractGrants
Funding Acknowledgements
This work was supported by funds from GlaxoSmithKline from whom the academic members of the ADOPT Steering Committee (B. Z., S. M. H., W. H. H., R. R. H., J. M. L., G. V., and S. E. K.) received honoraria, consulting fees, and/or grant/research support.